Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?
作者信息
Zucker Stanley, Cao Jian
机构信息
Veterans Affairs Medical Center, Northport, NY, USA.
出版信息
Cancer Biol Ther. 2009 Dec;8(24):2371-3. doi: 10.4161/cbt.8.24.10353. Epub 2009 Dec 19.
Abstract
摘要
相似文献
1
Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?癌症治疗中的选择性基质金属蛋白酶（MMP）抑制剂：准备好进入黄金时期了吗？
Cancer Biol Ther. 2009 Dec;8(24):2371-3. doi: 10.4161/cbt.8.24.10353. Epub 2009 Dec 19.
2
Matrix metalloproteinase inhibitors and cancer: trials and tribulations.基质金属蛋白酶抑制剂与癌症：试验与磨难
Science. 2002 Mar 29;295(5564):2387-92. doi: 10.1126/science.1067100.
3
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.肿瘤微环境——观点：验证基质金属蛋白酶作为癌症治疗的药物靶点和抗靶点
Nat Rev Cancer. 2006 Mar;6(3):227-39. doi: 10.1038/nrc1821.
4
Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials.基质金属蛋白酶抑制剂（MMPIs）：I期临床试验的开始还是III期临床试验的终止。
Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):177-203. doi: 10.1023/a:1023047431869.
5
Development of matrix metalloproteinase inhibitors in cancer therapy.癌症治疗中基质金属蛋白酶抑制剂的研发。
J Natl Cancer Inst. 2001 Feb 7;93(3):178-93. doi: 10.1093/jnci/93.3.178.
6
Towards third generation matrix metalloproteinase inhibitors for cancer therapy.迈向用于癌症治疗的第三代基质金属蛋白酶抑制剂。
Br J Cancer. 2006 Apr 10;94(7):941-6. doi: 10.1038/sj.bjc.6603043.
7
Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?基质金属蛋白酶抑制剂：它们在抗癌治疗中有一席之地吗？
Pharmacotherapy. 2002 Jun;22(6):705-20. doi: 10.1592/phco.22.9.705.34062.
8
Matrix metalloproteinases. Novel targets for directed cancer therapy.基质金属蛋白酶。定向癌症治疗的新靶点。
Drugs Aging. 1997 Sep;11(3):229-44. doi: 10.2165/00002512-199711030-00006.
9
[Expression of matrix metalloproteinases in patients with malignant tumors].[基质金属蛋白酶在恶性肿瘤患者中的表达]
Medicina (Kaunas). 2004;40(12):1143-50.
10
Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.基质金属蛋白酶抑制剂用于癌症药物设计的近期机遇
Expert Opin Drug Discov. 2018 Jan;13(1):75-87. doi: 10.1080/17460441.2018.1398732. Epub 2017 Oct 31.
引用本文的文献
1
Protease Inhibition Mechanism of Camelid-like Synthetic Human Antibodies.骆驼科类合成人源抗体的蛋白酶抑制机制
Biochemistry. 2020 Oct 13;59(40):3802-3812. doi: 10.1021/acs.biochem.0c00690. Epub 2020 Sep 30.
2
Recent insights into natural product inhibitors of matrix metalloproteinases.基质金属蛋白酶天然产物抑制剂的最新研究进展
Medchemcomm. 2019 Oct 7;10(12):2024-2037. doi: 10.1039/c9md00165d. eCollection 2019 Dec 1.
3
Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases.新型靶向促血管生成基质金属蛋白酶药物的作用机制。
Front Immunol. 2019 Jun 4;10:1278. doi: 10.3389/fimmu.2019.01278. eCollection 2019.
4
Evaluation of MMP Inhibitors Isolated from Fructus.评价从榼藤子中分离得到的基质金属蛋白酶抑制剂
Molecules. 2019 Feb 8;24(3):604. doi: 10.3390/molecules24030604.
5
Reducing proteolytic liability of a MMP-14 inhibitory antibody by site-saturation mutagenesis.通过定点饱和突变降低 MMP-14 抑制性抗体的蛋白水解易损性。
Protein Sci. 2019 Mar;28(3):643-653. doi: 10.1002/pro.3567. Epub 2019 Jan 11.
6
Use of a novel camelid-inspired human antibody demonstrates the importance of MMP-14 to cancer stem cell function in the metastatic process.一种受骆驼科动物启发的新型人类抗体的应用证明了基质金属蛋白酶-14在转移过程中对癌症干细胞功能的重要性。
Oncotarget. 2018 Jun 29;9(50):29431-29444. doi: 10.18632/oncotarget.25654.
7
Generation of Highly Selective MMP Antibody Inhibitors.高选择性基质金属蛋白酶抗体抑制剂的生成。
Methods Mol Biol. 2018;1731:307-324. doi: 10.1007/978-1-4939-7595-2_26.
8
Synthesis and Evaluation of New Oxadiazole, Thiadiazole, and Triazole Derivatives as Potential Anticancer Agents Targeting MMP-9.新型恶二唑、噻二唑和三唑衍生物作为靶向基质金属蛋白酶-9的潜在抗癌剂的合成与评价
Molecules. 2017 Jul 4;22(7):1109. doi: 10.3390/molecules22071109.
9
Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.基质金属蛋白酶作为癌症中可控递送的靶点：上调与表达分析
J Control Release. 2017 Aug 10;259:62-75. doi: 10.1016/j.jconrel.2017.01.034. Epub 2017 Jan 31.
10
Identification of highly selective MMP-14 inhibitory Fabs by deep sequencing.通过深度测序鉴定高选择性基质金属蛋白酶-14抑制性单克隆抗体片段
Biotechnol Bioeng. 2017 Jun;114(6):1140-1150. doi: 10.1002/bit.26248. Epub 2017 Feb 20.
本文引用的文献
1
A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth.一种新型、选择性的膜型基质金属蛋白酶-1（MT1-MMP）抑制剂可降低癌细胞的迁移能力和肿瘤生长。
Cancer Biol Ther. 2009 Dec;8(24):2362-70. doi: 10.4161/cbt.8.24.10139. Epub 2009 Dec 19.
2
A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis.一个对TrkB诱导的上皮-间质转化样转变、失巢凋亡抗性和转移至关重要的Twist-蜗牛轴。
Mol Cell Biol. 2009 Jul;29(13):3722-37. doi: 10.1128/MCB.01164-08. Epub 2009 May 4.
3
Optical proteolytic beacons for in vivo detection of matrix metalloproteinase activity.用于体内检测基质金属蛋白酶活性的光学蛋白水解信标。
Methods Mol Biol. 2009;539:155-74. doi: 10.1007/978-1-60327-003-8_9.
4
Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis.基质金属蛋白酶-14的选择性抑制可阻断肿瘤生长、侵袭和血管生成。
Cancer Res. 2009 Feb 15;69(4):1517-26. doi: 10.1158/0008-5472.CAN-08-3255. Epub 2009 Feb 10.
5
Rac activation and inactivation control plasticity of tumor cell movement.Rac的激活与失活控制肿瘤细胞运动的可塑性。
Cell. 2008 Oct 31;135(3):510-23. doi: 10.1016/j.cell.2008.09.043.
6
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.曲妥珠单抗、紫杉醇和卡铂与曲妥珠单抗和紫杉醇对比治疗HER-2过表达转移性乳腺癌女性患者的随机III期研究。
J Clin Oncol. 2006 Jun 20;24(18):2786-92. doi: 10.1200/JCO.2005.04.1764.
7
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.肿瘤微环境——观点：验证基质金属蛋白酶作为癌症治疗的药物靶点和抗靶点
Nat Rev Cancer. 2006 Mar;6(3):227-39. doi: 10.1038/nrc1821.
8
MT1-MMP: a potent modifier of pericellular microenvironment.基质金属蛋白酶-1：细胞周围微环境的强效调节剂。
J Cell Physiol. 2006 Jan;206(1):1-8. doi: 10.1002/jcp.20431.
9
A bioinorganic perspective on matrix metalloproteinase inhibition.基质金属蛋白酶抑制的生物无机视角。
Curr Top Med Chem. 2004;4(15):1551-73. doi: 10.2174/1568026043387368.
10
Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196.马立马司他对比安慰剂用于一线化疗后疾病缓解或稳定的转移性乳腺癌患者的随机III期试验：东部肿瘤协作组E2196试验
J Clin Oncol. 2004 Dec 1;22(23):4683-90. doi: 10.1200/JCO.2004.08.054.
Zotero 插件